Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia
Key Highlights
- ➤U.S. real-world cohort: 67% remained on imetelstat therapy at six months
- ➤13 Korean patients linked early cytopenias with better clinical outcomes
- ➤Two Korean patients achieved over one year of red blood cell transfusion independence
- ➤IMerge evidence associated sustained transfusion independence with improved health-related outcomes
- ➤RYTELO approved in U.S. and European Union for certain lower-risk MDS patients
Expert Statements
Joseph E. Eid, Executive Vice President, Research and Development and Chief Medical Officer of Geron
“We’re encouraged by the growing interest in imetelstat across the global hematology community, supported by both the clinical evidence from IMerge and an expanding body of real-world evidence in lower-risk MDS”
Joseph E. Eid, Executive Vice President, Research and Development and Chief Medical Officer of Geron
“These presentations provide an important opportunity to share evidence relevant to patient populations across regions and engage with clinicians as we evaluate opportunities to bring imetelstat’s potential to more people living with LR-MDS around the world.”
Presentations feature real-world experience and clinical evidence in lower-risk MDS, underscoring growing global scientific engagement with imetelstat
FOSTER CITY, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced two oral presentations and one poster presentation highlighting imetelstat in patients with lower-risk myelodysplastic syndromes (LR-MDS) at the 88(th) Annual Meeting of the Japanese Society of Hematology and the 2026 Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology. These presentations will feature real-world evidence and findings from the Phase 3 IMerge trial.
Get started
Create a free account to read the full story.